Treatment | EETs + DHETs | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
n | 14,15 | 11,12 | 8,9 | 5,6 | Total | ||||||
nmol/mg microsomal protein/min ± S.E. | |||||||||||
TCDD | 11 | 0.188 ± 0.019 | 0.175 ± 0.014 | 0.200 ± 0.020 | 0.283 ± 0.029 | 0.844 ± 0.067 | |||||
(22 ± 1.2)c*** | (21 ± 1.5) | (24 ± 1.2)c*** | (33 ± 1.8)a,c*** | ||||||||
PB | 3 | 0.339 ± 0.014 | 0.162 ± 0.019 | 0.294 ± 0.001 | 0.067 ± 0.003 | 0.862 ± 0.027 | |||||
(40 ± 0.8)a,b,*** | (19 ± 2)a | (34 ± 0.9)a,b** | (7 ± 0.6)a,b*** | ||||||||
ALB | 4 | 0.161 ± 0.014 | 0.123 ± 0.014 | 0.168 ± 0.009 | 0.182 ± 0.011 | 0.635 ± 0.043 | |||||
(25 ± 0.9)c** | (19 ± 1.1)a | (27 ± 1.8) | (29 ± 0.3)c*** | ||||||||
BZY | 4 | 0.193 ± 0.033 | 0.145 ± 0.024 | 0.142 ± 0.028 | 0.126 ± 0.017 | 0.605 ± 0.099 | |||||
(32 ± 0.7)b***,c** | (24 ± 0.6) | (23 ± 1.2)c* | (21 ± 1.6)b**,c* | ||||||||
OP | 4 | 0.191 ± 0.005 | 0.108 ± 0.009 | 0.140 ± 0.008 | 0.058 ± 0.007 | 0.497 ± 0.018 | |||||
(38 ± 1.6)a,b*** | (22 ± 1.3)a | (28 ± 1.4)a | (12 ± 1.3)a,b*** | ||||||||
R76713 | 13 | 0.178 ± 0.018 | 0.119 ± 0.008 | 0.190 ± 0.013 | 0.130 ± 0.013 | 0.616 ± 0.040 | |||||
(28.5 ± 1.6)a,b**,c** | (19.5 ± 0.7)a | (31 ± 1.2)b** | (21 ± 1.7)b***,c** | ||||||||
TBZ | 4 | 0.045 ± 0.008 | 0.024 ± 0.006 | 0.038 ± 0.008 | 0.021 ± 0.005 | 0.128 ± 0.013 | |||||
|
| (35 ± 4.3)b*** | (20 ± 4.5) | (29 ± 4.4) | (16 ± 3.4)b*** |
|
↵ a Significantly different from all other regioisomers for the same treatment (exceptions: ALB, 11,12 did not differ from 14,15; R76713, 11,12 did not differ from 5,6 nor 14,15 from 8,9). b Relative regioisomer production significantly different from TCDD. c Relative regioisomer production significantly different from PB. For b and c: * p < 0.05, ** p < 0.01, *** p < 0.001. For a: TCDD, p < 0.01; PB, p < 0.01, except p < 0.05 for 8,9 vs. 14,15; ALB, p < 0.05; OP, p < 0.001, except p < 0.01 for 11,12 vs. 8,9; R76713, p < 0.01, except p < 0.05 for 14,15. n = number of independent experiments. Abbreviations as in Fig. 2.